Opinion

Video

Clinical Perspectives from the ARANOTE Trial in Metastatic Hormone-Sensitive Prostate Cancer

Author(s):

Fred Saad, CQ, MD, FRCS, FCAHS

Key Takeaways

  • Darolutamide's structure limits blood-brain barrier penetration, reducing central nervous system side effects and improving safety.
  • It effectively delays metastasis and prolongs survival in non-metastatic castration-resistant prostate cancer.
SHOW MORE

Fred Saad, CQ, MD, FRCS, FCAHS, discusses how darolutamide offers potential advantages over other androgen receptor–targeted therapies for metastatic prostate cancer, including its unique molecular structure, favorable safety profile, and efficacy in specific clinical scenarios.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video Content above is prompted by the following:

      • What are some of the benefits of darolutamide over other androgen receptor–targeted therapies?
      Related Videos
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Checkpoint Inhibitors for Treatment of NMIBC
      Checkpoint Inhibitors for Treatment of NMIBC
      Communication of Treatment Options for High-Risk NMIBC
      Communication of Treatment Options for High-Risk NMIBC
      3 experts are featured in this series.
      Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
      3 experts are featured in this series.
      Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
      1 expert in this video
      BPH: The Patient Journey
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
      Addressing Remaining Unmet Needs in mCRPC
      Addressing Remaining Unmet Needs in mCRPC
      Use and Sequencing of Novel Treatments in NMIBC
      Use and Sequencing of Novel Treatments in NMIBC
      The DORA Trial
      The DORA Trial
      Related Content
      Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com
      April 3rd 2025

      CD46-targeting ADC shows encouraging clinical activity in mCPRC

      Hannah Clarke
      The company plans to initiate the phase 2 monotherapy trial by mid-year.
      Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
      January 14th 2025

      Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

      Wayne Kuang, MD Steven Maislos, MD
      Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
      FDA updates in urology: March 2025
      April 1st 2025

      FDA updates in urology: March 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from March 2025.
      Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
      November 27th 2024

      Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

      Wayne Kuang, MD Bilal Chughtai, MD
      Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
      NeuroSAFE procedure for RARP leads to improved erectile function
      March 27th 2025

      NeuroSAFE procedure for RARP leads to improved erectile function

      Hannah Clarke
      “Our results show that by using NeuroSAFE, nearly twice as many men don’t have to face potentially life-changing loss of erectile function after prostate surgery,” says Professor Greg L. Shaw.
      Data reinforce isodose MHFRT as standard of care radiotherapy regimen
      March 22nd 2025

      Data reinforce isodose MHFRT as standard of care radiotherapy regimen

      Hannah Clarke
      “These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.
      © 2025 MJH Life Sciences

      All rights reserved.